2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Omics Technologies, Serologic Tests, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Biological Processes, Apoptosis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Animal Model
PAPER

2990 Modeled impact of unvaccinated transmission networks on COVID-19 mortality among immunocompromised patients with hematologic malignancies and transplantation

Basem William, MD, MRCP(UK), FACP
1 OhioHealth Blood and Marrow Transplant Program, Columbus, Ohio, United States

Background:
Immunocompromised patients, particularly those with hematologic malignancies and transplant recipients, experienced high COVID-19 mortality despite vaccination-era improvements. Because vaccine refusal can create susceptible transmission clusters, we modeled the effect of unvaccinated transmission networks on SARS-CoV-2 exposure and mortality among immunocompromised populations.

Methods:
We developed a deterministic exposure-reduction and threshold model using publicly available CDC parameters, vaccine efficacy/effectiveness studies, household transmission data, and published mortality estimates for immunocompromised cohorts. Population groups included unvaccinated individuals, vaccinated immunocompetent individuals, and immunocompromised individuals. We modeled residual transmission as:

R_eff(p) = R0 × [(1 - p) + p × q]

where p is vaccine uptake and q is residual transmission after vaccination. Central assumptions were R0 = 3.0, vaccine effectiveness against infection of 85%, and 40% reduction in onward transmission after breakthrough infection, yielding q = 0.09. Mortality reductions were estimated per 100,000 subgroup members using infection attack-rate reductions and published mortality-after-infection estimates: 2-8% for broadly immunocompromised patients, 21-34% for hematologic malignancies, and approximately 21% for transplant populations.

Results:
In the central model, unvaccinated individuals comprising 20% of the population contributed approximately 71% of residual infection pressure to immunocompromised individuals. Complete separation from unvaccinated transmission networks reduced modeled exposure risk by approximately 71%, assuming no cross-contact. At a 20% infection attack rate, this corresponded to approximately 569 deaths averted per 100,000 broadly immunocompromised patients using a 4% mortality assumption. Estimated deaths averted were substantially higher among hematologic malignancy patients, approximately 2,986-4,835 per 100,000 using mortality estimates of 21-34%, and approximately 2,986 per 100,000 among transplant recipients using a 21% mortality estimate.

Threshold analysis showed that, under central assumptions, the vaccine uptake level required to prevent sustained transmission was approximately 73%. A 10-percentage-point increase in uptake had the greatest effect near this threshold. Increasing uptake from 60% to 70% reduced modeled immunocompromised infection attack rate from 27.9% to 8.3%, averting approximately 783 deaths per 100,000 broadly immunocompromised patients, 4,895 deaths per 100,000 hematologic malignancy patients, and 4,112 deaths per 100,000 transplant recipients. Increasing uptake from 65% to 75% crossed the modeled herd-control threshold and averted approximately 760, 4,750, and 3,990 deaths per 100,000 in these respective groups.

Conclusions:
Unvaccinated transmission networks may disproportionately increase COVID-19 mortality risk among immunocompromised patients by sustaining local transmission and increasing importation pressure. In this theoretical model, increasing vaccine uptake by 10 percentage points produced the largest mortality reduction when community coverage approached the herd-control threshold. These findings support prioritizing high local vaccine coverage, exposure reduction, and transmission control around patients with hematologic malignancies and transplant recipients.

Basem William, MD, MRCP(UK), FACP: Incyte - Honoraria; Kyowa Kirin - Honoraria; Adaptive - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); PPD - Consultancy (Includes expert testimony); Natera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Guidepoint Global - Consultancy (Includes expert testimony)